Stem Cell Markets

Table of Contents

1. Overview

• 1.1 Statement of Report
• 1.2 Scope of the Report
• 1.3 Methodology
• 1.4 Executive Summary

2. Biology of Stem Cells

• 2.1 Scope of this Chapter
• 2.2 Basic Properties of Stem Cells and Their Classification
• 2.3 Differentiation of Stem Cells
  • 2.3.1 Neural and Neuronal Differentiation
  • 2.3.2 Cardiomyogenic Differentiation of ESCs
  • 2.3.3 Differentiation of Mesenchymal Stem/Progenitor Cells
• 2.4 Self-Renewal of Stem Cells
• 2.5 Dedifferentiation and Nuclear Reprogramming
• 2.6 Functional Proliferation of Adult Mature Cells
• 2.7 Nanog Promotes Transfer of Pluripotency After Cell Fusion
• 2.8 MicroRNAs in Stem Cell Development
• 2.9 Stem Cell Therapy

3. Market Analysis of the Stem Cell Space

• 3.1 Scope of this Chapter
• 3.2 Overall Market Opportunity and Segmentation of the Total Stem Cell Marketplace
• 3.3 Potential Stem Cell Commercial Applications
  • 3.3.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity
• 3.4 Results of Primary Market Survey to Characterize Qualitative and Quantitative Trends in the Stem Cells Space
  • 3.4.1 Characteristics of the Respondent Pool
  • 3.4.2 Utilization of the Different Classes of Stem Cells
  • 3.4.3 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed in Research
  • 3.4.4 Evolution of Research Activities with Different Types of Stem Cells: Current Usage Trends and Usage in 12 to 18 Months
  • 3.4.5 Types of Stem Cell Research Activities Performed by the End-User Community
  • 3.4.6 Challenges Facing Stem Cell Researchers
  • 3.4.7 Market Drivers and Research Questions Being Addressed in the Stem Cell Space
  • 3.4.8 Summary of Challenges and Opportunities in the Stem Cell Space Based on TriMark' s Analysis
  • 3.4.9 Unmet Product Needs in the Stem Cell Research Space and Licensing/IP Constraints
• 3.5 Competitive Landscape of the Stem Cell Marketplace
  • 3.5.1 SWOT Analysis of the Major Stem Cell Market Segments
• 3.6 Market Size and Forecasts

4. Worldwide Landscape of Stem Cell Research

• 4.1 Scope of this Chapter
• 4.2 Global Embryonic Stem Cell Research
  • 4.2.1 Top Research Institutions Worldwide in the Stem Cells Space and Global "Hot Spots" for Research and Therapeutics
• 4.3 Stem Cell Research in the U.S.
  • 4.3.1 Proposition 71 in the State of California
• 4.4 Intellectual Property (IP) Landscape Surrounding Stem Cells
• 4.5 Who Will Finance Stem Cell Research?
  • 4.5.1 U.S. Government Policy on Stem Cell Research
  • 4.5.2 Current Federal Policy
    • 4.5.2.1 Moral Issues Affecting Pre-Obama Federal Policy
    • 4.5.2.2 Significance and Requirements for Federal Funding
    • 4.5.2.3 Draft Guidelines for the new NIH stem cell funding policy
  • 4.5.3 International Law
    • 4.5.3.1 Australia
    • 4.5.3.2 U.K.
    • 4.5.3.3 Canada
    • 4.5.3.4 China
    • 4.5.3.5 Germany
    • 4.5.3.6 Switzerland
    • 4.5.3.7 Japan
    • 4.5.3.8 Israel
    • 4.5.3.9 Singapore
  • 4.5.4 Technological and Economical Disadvantages for the U.S.

5. Therapeutic Areas and Research Programs in the Stem Cell Space

• 5.1 Scope of this Chapter
• 5.2 Therapeutic and Other Markets Addressed by Stem Cells
  • 5.2.1 Hematopoietic Stem Cells (HSCs)
  • 5.2.2 Stem Cell Therapeutics for Cardiac and Ischemic Diseases
  • 5.2.3 Stem Cell Therapeutics for Type I Diabetes
  • 5.2.4 Stem Cell Therapeutics for Orthopedic Diseases
  • 5.2.5 Stem Cell Therapeutics for Neurological Diseases
• 5.3 Off-the-Shelf Stem Cells Being Developed

6. Company Profiles

• 6.1 Aastrom Biosciences
• 6.2 Advanced Cell Technology
• 6.3 BioE
• 6.4 Bioheart
• 6.5 Cryo-Cell International
• 6.6 ES Cell International
• 6.7 Gamida Cell
• 6.8 GenVec
• 6.9 Geron
• 6.10 NeuroGeneration
• 6.11 Osiris Therapeutics
• 6.12 Pluristem Therapeutics
• 6.13 ReNeuron
• 6.14 StemCells, Inc.
• 6.15 Titan Pharmaceuticals
• 6.16 ViaCell (now PerkinElmer)

Appendix 1. Glossary of Terms in Stem Cell Biology

INDEX OF FIGURES

• Figure 2.1: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts
• Figure 2.2: Classification of Stem Cells: Embryonic Stem Cells Versus Adult Stem Cells
• Figure 2.3: Somatic Cell Nuclear Transfer (SCNT)
• Figure 3.1: Segmentation of the Stem Cell Marketplace Based Upon Commercial Offerings-Products and Services
• Figure 3.2: Geographical Breakout of Stem Cell End-User Survey Respondents
• Figure 3.3: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-User Survey Respondents
• Figure 3.4: Survey Respondents That Are Studying Stem Cells or Using Stem Cells in Their Research
• Figure 3.5: Length of Time Survey Respondent Pool Has Been Studying Stem Cells or Using Stem Cells in Its Research Activities
• Figure 3.6: Utilization/Research with Different Stem Cell Types
• Figure 3.7: Number of Experiments Involving Stem Cells Conducted Per Week
• Figure 3.8: Differences with Respect to Usage of Stem Cell Types
• Figure 3.9: Research Dollars Spent Monthly on Research/Studies with Different Stem Cell Types
• Figure 3.10: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)
• Figure 3.11: Growth in End-User Utilization of Various Stem Cell Types
• Figure 3.12: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
• Figure 3.13: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
• Figure 3.14: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers
• Figure 3.15: Current End-User Utilization Category for Adult Stem Cells (ASCs)
• Figure 3.16: Current End-User Utilization Category for Human Embryonic Stem Cells (hESCs)
• Figure 3.17: Current End-User Utilization Category for Human Cord Blood Stem Cells
• Figure 3.18: Current End-User Utilization Category for Animal Stem Cells
• Figure 3.19: Current End-User Utilization Category for Cancer Stem Cells
• Figure 3.20: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)
• Figure 3.21: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)
• Figure 3.22: Challenges in the Study or Utilization of Human Cord Blood Stem Cells
• Figure 3.23: Challenges in the Study or Utilization of Animal Stem Cells
• Figure 3.24: Challenges in the Study or Utilization of Cancer Stem Cells
• Figure 3.25: Top Unmet Needs in Commercial Products in the Stem Cell Research Space
• Figure 3.26: U.S. Stem Cell Therapy Market Sales, 2005-2016
• Figure 4.1: Stem Cell Research Worldwide

INDEX OF TABLES

• Table 2.1: The Different Types of Stem Cells and Their Properties
• Table 2.2: Adult Stem Cell (ASC) Differentiation Properties
• Table 3.1: Characteristics of Different Stem Cell Types and Associated Market Opportunities
• Table 3.2: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cells
• Table 3.3: Selected Cord Blood Banks in the U.S.
• Table 3.4: Selected Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space
• Table 3.5: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells
• Table 3.6: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months
• Table 3.7: Market Share of Companies/Institutions Offering Different Stem Cells to Researchers
• Table 3.8: Market Share of Companies/Institutions Offering Reagents for Stem Cell Research
• Table 3.9: The U.S. Stem Cell Therapy Market Forecast, 2005-2016
• Table 4.1: Major Milestones in Stem Cell Research and Associated Timeline, 1981-2009
• Table 4.2: Selected Stem Cell Hot Spots Worldwide Administering Non-FDA Approved Stem Cell Therapeutic Regimens
• Table 4.3: NIH Funding of Stem Cell Research in the U.S., 2004-2009
• Table 4.4: Snapshot of the Current Key Stem Cell Patents
• Table 5.1: Estimate of Potential Market Opportunity for Stem Cell-based Therapeutics
• Table 5.2: Autologous Versus Allogeneic Cell Therapy
• Table 5.3: Diseases Treated with HSC Transplantation Today
• Table 5.4: HSC Sources and Their Properties
• Table 5.5: Stem Cell Therapeutics for Hematological Diseases in Development
• Table 5.6: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development
• Table 5.7: Stem Cell-based Therapeutics for Vascular Diseases in Development
• Table 5.8: Stem Cell Therapeutics for Type I Diabetes in Development
• Table 5.9: Stem Cell Therapeutics for Orthopedic Disease in Development
• Table 5.10: Stem Cell Therapeutics for Neurological Disease in Development
• Table 5.11: Segmentation of the Allogeneic Cell Therapy Market